UnitedHealth Group (UNH) Stock Forecast & Price Target

$608.38 +1.59 (+0.26%)

(As of 11/27/2024 ET)

UnitedHealth Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
0

Hold
3

Buy
19

Based on 22 Wall Street analysts who have issued ratings for UnitedHealth Group in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 3 have given a hold rating, 17 have given a buy rating, and 2 have given a strong buy rating for UNH.

Consensus Price Target

$618.26
1.62% Upside

According to the 22 analysts' twelve-month price targets for UnitedHealth Group, the average price target is $618.26. The highest price target for UNH is $675.00, while the lowest price target for UNH is $559.00. The average price target represents a forecasted upside of 1.62% from the current price of $608.38.

Get the Latest News and Ratings for UNH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for UnitedHealth Group and its competitors.

UNH Analyst Ratings Over Time

Type	Current Forecast 11/30/23 to 11/29/24	1 Month Ago 10/31/23 to 10/30/24	3 Months Ago 9/1/23 to 8/31/24	1 Year Ago 11/30/22 to 11/30/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	18 Buy rating(s)	14 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$618.26	$615.53	$614.17	$579.65
Forecasted Upside	1.62% Upside	9.19% Upside	4.06% Upside	4.82% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

2024 Election Year Stocks: Uncover Hidden Gems! (Ad)

In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.

Secure your copy now by clicking this link.

UNH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

UNH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

UnitedHealth Group Stock vs. The Competition

Type	UnitedHealth Group	Medical Companies	S&P 500
Consensus Rating Score	2.95	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	1.62% Upside	24,757.92% Upside	6.55% Upside
News Sentiment Rating	Positive News See Recent UNH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/27/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$603.00 ➝ $655.00	+7.63%
10/18/2024	TD Cowen 4 of 5 stars		Boost Target	Buy ➝ Buy	$601.00 ➝ $609.00	+7.84%
10/17/2024	Hsbc Global Res 0 of 5 stars	M. Herholdt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/17/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
10/16/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$680.00 ➝ $650.00	+13.16%
10/16/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$640.00 ➝ $625.00	+9.19%
Unveiled: NVIDIA’s "Secret Royalty" Program (Ad) Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip? Click Here to learn how to get in now >>>
10/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$591.00 ➝ $644.00	+12.51%
10/16/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$632.00 ➝ $605.00	+5.69%
10/16/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$615.00 ➝ $595.00	+7.31%
10/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$675.00 ➝ $650.00	+17.23%
10/16/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$615.00 ➝ $610.00	+10.02%
10/11/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight ➝ Overweight	$675.00 ➝ $675.00	+12.94%
7/17/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$570.00 ➝ $600.00	+4.95%
7/17/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$525.00 ➝ $630.00	+11.23%
7/17/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$597.00 ➝ $640.00	+16.60%
7/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$481.00 ➝ $647.00	+17.88%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$546.00 ➝ $559.00	+15.75%
4/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$545.00 ➝ $562.00	+13.96%
4/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$566.00 ➝ $571.00	+18.76%
3/13/2024	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
1/17/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$610.00	+15.23%
7/18/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$595.00 ➝ $603.00	+24.55%
7/11/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$600.00 ➝ $549.00	+18.56%
6/14/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$625.00 ➝ $560.00	+13.98%
4/17/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$590.00 ➝ $600.00	+17.24%
4/14/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Strong-Buy	$630.00	+24.75%
12/7/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$590.00 ➝ $610.00	+13.11%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:35 AM ET.

Should I Buy UnitedHealth Group Stock? UNH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 21, 2024. Please send any questions or comments about these UnitedHealth Group pros and cons to contact@marketbeat.com.

UnitedHealth Group
Bull Case

Here are some ways that investors could benefit from investing in UnitedHealth Group:

UnitedHealth Group recently reported a quarterly earnings per share (EPS) of $7.15, exceeding analysts' expectations of $7.00, indicating strong financial performance and effective management.
The company achieved a revenue of $100.82 billion for the quarter, surpassing estimates and reflecting a year-over-year growth of 9.2%, showcasing its robust business model and market demand.
With a current stock price of $602.29, UnitedHealth Group has shown resilience in the market, maintaining a strong position despite fluctuations.
The company has a consensus rating of "Moderate Buy" from analysts, with a significant number of buy ratings, suggesting positive sentiment and potential for future growth.
UnitedHealth Group offers a quarterly dividend of $2.10, translating to an annual yield of 1.39%, providing investors with a steady income stream alongside potential capital appreciation.

UnitedHealth Group
Bear Case

Investors should be bearish about investing in UnitedHealth Group for these reasons:

Recent downgrades from analysts, including a reduction in target prices by several firms, may indicate concerns about the company's future performance and market conditions.
The stock has a relatively high price-to-earnings (P/E) ratio of 39.12, which could suggest that it is overvalued compared to its earnings, potentially limiting upside for new investors.
UnitedHealth Group's debt-to-equity ratio of 0.74 indicates a moderate level of debt, which could pose risks in a rising interest rate environment or economic downturn.
Despite strong revenue growth, the company's net margin of 3.63% suggests that profitability may be under pressure, which could affect future earnings and dividends.
Market volatility and regulatory changes in the healthcare sector could impact UnitedHealth Group's operations and profitability, introducing uncertainty for investors.

UNH Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for UnitedHealth Group is $618.26, with a high forecast of $675.00 and a low forecast of $559.00.
: 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UnitedHealth Group in the last year. There are currently 3 hold ratings, 17 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" UNH shares.
: According to analysts, UnitedHealth Group's stock has a predicted upside of 1.62% based on their 12-month stock forecasts.
: Over the previous 90 days, UnitedHealth Group's stock had 2 downgrades and 1 upgrade by analysts.
: UnitedHealth Group has been rated by research analysts at Bank of America, Barclays, Cantor Fitzgerald, Hsbc Global Res, HSBC, KeyCorp, Morgan Stanley, Royal Bank of Canada, Stephens, TD Cowen, Truist Financial, and UBS Group in the past 90 days.
: Analysts like UnitedHealth Group more than other "medical" companies. The consensus rating score for UnitedHealth Group is 2.95 while the average consensus rating score for "medical" companies is 2.80. Learn more on how UNH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Top investors are backing this “unlisted” stock (Ad)

When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying attention. That’s why top firms like SoftBank and Maveron have already backed their latest venture, a company that’s transforming the $1.3 trillion vacation home market.

Learn more about becoming a shareholder in this real estate disruptor before their share price chang

This page (NYSE:UNH) was last updated on 11/29/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

UnitedHealth Group (UNH) Stock Forecast & Price Target